Effects of Advanced Glycation End Products and Their Receptor on Osteoporosis in Type 2 Diabetes Mellitus
10.16156/j.1004-7220.2025.03.032
- VernacularTitle:晚期糖基化终末产物及其受体对2型糖尿病骨质疏松的影响
- Author:
Peipei SHI
1
;
He GONG
1
Author Information
1. 北京航空航天大学 生物与医学工程学院,生物力学与力生物学教育部重点实验室,北京市生物医学工程高精尖创新中心,北京 100191;杭州市北京航空航天大学国际创新研究院(北京航空航天大学国际创新学院)医工交叉科创中心,杭州 311115
- Publication Type:Journal Article
- Keywords:
type 2 diabetes mellitus;
osteoporosis;
advanced glycation end products;
bone turnover;
drug intervention
- From:
Journal of Medical Biomechanics
2025;40(2):485-491
- CountryChina
- Language:Chinese
-
Abstract:
Osteoporosis caused by type 2 diabetes mellitus(T2DM)increases the risk of fracture and post-fracture mortality.However,the pathogenesis of the disease remains unclear,resulting in a lack of effective strategies for its prevention and treatment.In this review,firstly,the effects of advanced glycation end products(AGEs)produced by non-enzymatic glycation on bone matrix composition,bone structure,and mechanical properties of T2DM are summarized.Then,the biological mechanism of AGEs and receptor for AGEs(RAGE)affecting bone degeneration in T2DM is clarified.Finally,antidiabetic and other drugs that are beneficial to bone anabolism are discussed.These drugs positively affect bone quality through inhibiting AGE/RAGE signaling pathway.Accordingly,it is expected to provide potential intervention targets and ideas for the prevention and treatment of T2DM-related osteoporosis.
